DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $2.52B
• Dividend Yield: 5.08%
• Average Volume (3M): 3.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: -5.78%
• EPS Growth: -445.83%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.52
• Shares Outstanding: 199,483,860
• 10 Day Avg. Volume: 2,480,165
• 30 Day Avg. Volume: 3,138,602
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.99
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 13.73
• Enterprise Value/Market Cap: 2.11
• Enterprise Value/Revenue: 1.44
• Enterprise Value/Gross Profit: 2.79
• Enterprise Value/Ebitda: -7.66
• 1Y Price Target: $15.65
• Price Target Upside: 24.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15

• Rating: 45 Neutral
• Price Target: $13.00 ▲(3.09% Upside)

DENTSPLY SIRONA's overall stock score is primarily impacted by its financial performance challenges, including declining revenue and increased leverage. The technical analysis provides mixed signals, with bearish momentum and potential overbought conditions. The valuation reflects financial struggles with a negative P/E ratio, but the high dividend yield offers some appeal. The earnings call provided some positive insights, such as improved margins, but overall sentiment remains cautious due to sales declines and impairment charges.

Positive Factors

DS Core Platform Growth

The growth of the DS Core platform indicates strong adoption of digital solutions, enhancing DENTSPLY SIRONA's competitive edge and supporting long-term revenue potential.

Adjusted EBITDA Margin Expansion

Improved EBITDA margins reflect effective cost management, which enhances profitability and provides financial resilience in challenging market conditions.

SEC Investigation Conclusion

The favorable conclusion of the SEC investigation removes regulatory uncertainty, allowing the company to focus on strategic initiatives and operational improvements.

Negative Factors

Decline in Global Sales

The decline in global sales highlights challenges in maintaining market share and revenue growth, which could impact long-term financial performance.

Rising Debt Levels

Increased leverage can strain financial flexibility and cash flow, posing risks to the company's ability to invest in growth and innovation.

Impairment Charges

Significant impairment charges indicate potential overvaluation of assets, affecting financial health and signaling operational challenges in certain segments.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA (XRAY) is a leading global manufacturer of dental products and technologies, specializing in digital imaging solutions, including X-ray systems. The company operates primarily in the dental sector, providing a wide range of products that enhance dental care and treatment. DENTSPLY SIRONA's core offerings include dental imaging equipment, CAD/CAM systems, dental consumables, and equipment for restorative, preventive, and orthodontic procedures, serving dental professionals and laboratories worldwide.

How the Company Makes Money

DENTSPLY SIRONA generates revenue through multiple streams, primarily from the sale of dental equipment and consumables. Their core revenue comes from the manufacturing and distribution of dental imaging systems, including X-ray machines and digital imaging software, which are sold to dental practices and clinics. Additional revenue is derived from dental materials and supplies, such as restorative materials and orthodontic products. The company also benefits from recurring revenue through the sale of maintenance services and software upgrades for their imaging systems. Strategic partnerships with dental professionals, educational institutions, and other healthcare providers enhance their distribution network and market presence, contributing to their overall earnings. The company's commitment to innovation and product development further positions it to capitalize on emerging trends in dental technology, thereby expanding its revenue potential.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA is facing financial difficulties with declining revenues and profitability, as evidenced by negative margins and net losses. The balance sheet demonstrates moderate leverage and equity stability, but the negative ROE raises concerns about shareholder value. Cash flow management remains a relative strength, providing some stability amidst operational challenges.

Income Statement

The income statement shows declining revenue and profitability. The TTM (Trailing-Twelve-Months) data indicates a negative net profit margin of approximately -24.4% and a gross profit margin of 51.6%. The company has experienced a negative revenue growth rate of -0.5% compared to the previous year. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet reflects moderate stability with a debt-to-equity ratio of 1.2, indicating a balanced leverage. The equity ratio stands at approximately 33.2%, showing a reasonable proportion of equity financing. Return on Equity (ROE) is negative due to recent losses, which is a concern for potential investors.

Cash Flow

Cash flow analysis shows positive operating cash flow with an operating cash flow to net income ratio of approximately -0.49, indicating operating efficiencies despite net losses. Free cash flow growth rate is slightly negative, but free cash flow to net income ratio is positive, suggesting effective cash management relative to earnings challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.67B	3.79B	3.96B	3.92B	4.25B	3.34B
Gross Profit	1.90B	1.96B	2.09B	2.13B	2.36B	1.66B
EBITDA	-692.00M	-518.00M	232.00M	-677.00M	972.00M	336.00M
Net Income	-949.00M	-910.00M	-132.00M	-950.00M	411.00M	-83.00M
Balance Sheet
Total Assets	6.07B	5.75B	7.37B	7.64B	9.22B	9.34B
Cash, Cash Equivalents and Short-Term Investments	359.00M	272.00M	334.00M	365.00M	339.00M	438.00M
Total Debt	2.49B	2.27B	2.30B	2.09B	2.24B	2.41B
Total Liabilities	4.11B	3.81B	4.08B	3.83B	4.18B	4.37B
Stockholders Equity	1.96B	1.94B	3.29B	3.81B	5.04B	4.97B
Cash Flow
Free Cash Flow	138.00M	281.00M	228.00M	368.00M	515.00M	548.00M
Operating Cash Flow	283.00M	461.00M	377.00M	517.00M	657.00M	635.00M
Investing Cash Flow	-155.00M	-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
Financing Cash Flow	-62.00M	-302.00M	-307.00M	-329.00M	-379.00M	490.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Negative. The current price of 12.61 is below the 20-day moving average (MA) of 12.67, below the 50-day MA of 13.14, and below the 200-day MA of 14.91, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 31.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COO	―	$13.90B	34.42	5.01%	―	6.35%	12.94%
RMD	―	$36.03B	25.27	25.41%	0.87%	9.36%	29.56%
BDX	―	$51.22B	32.14	6.26%	2.33%	7.86%	14.24%
HOLX	―	$16.45B	30.67	11.38%	―	1.28%	-17.73%
BAX	―	$9.49B	―	―	3.68%	-21.20%	-371.78%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XRAY	―	$2.52B	―	-37.78%	5.08%	-5.78%	-445.83%

DENTSPLY SIRONA Corporate Events

DENTSPLY SIRONA SEC Investigation Concludes Favorably

On October 14, 2025, DENTSPLY SIRONA announced that the SEC has concluded its investigation, which began in May 2022, into the company’s financial reporting matters without recommending any enforcement action. This closure is seen as a significant and favorable development for the company, reflecting its cooperation with the SEC and potentially strengthening its position in the industry.

The most recent analyst rating on (XRAY) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Announces Leadership Transition for Rosenzweig

On October 2, 2025, DENTSPLY SIRONA announced that Richard C. Rosenzweig will transition from his role as Executive Vice President, Corporate Development, General Counsel, and Secretary to a non-executive position as Special Legal Advisor, effective October 3, 2025. This transition is part of a mutual agreement, and Mr. Rosenzweig will continue to serve in an advisory capacity until March 4, 2026, with a monthly fee and additional severance benefits, before becoming an independent contractor consultant for a year.

The most recent analyst rating on (XRAY) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Approves Retention Award for Executives

On September 19, 2025, DENTSPLY SIRONA‘s Board approved a one-time retention equity incentive award for executives, including Tony Johnson, to recognize his performance during a leadership transition. The award, valued at $2 million in stock options, aims to retain Johnson for three years, with options vesting on the third anniversary and expiring ten years from the grant date.

The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona Retains Wellspect Healthcare After Review

On September 8, 2025, Dentsply Sirona announced the completion of its strategic review of the Wellspect Healthcare business, deciding to retain it within its portfolio. This decision follows extensive evaluation and outreach, concluding that Wellspect, a leader in the global continence care market, will deliver greater financial and strategic benefits to stockholders as part of Dentsply Sirona, given its strong product pipeline and market potential.

The most recent analyst rating on (XRAY) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Faces Challenges Amid Growth Opportunities

DENTSPLY SIRONA’s latest earnings call reflected a challenging quarter marked by declines in sales across several regions and segments, particularly in the U.S. and CTS segment. Despite these hurdles, there were areas of stability and growth, such as the DS Core platform and Germany’s sales performance. However, the significant impact of tariffs and impairment charges weighed heavily on the overall sentiment.

Dentsply Sirona Reports Q2 2025 Financial Results

Dentsply Sirona, the world’s largest manufacturer of professional dental products and technologies, reported its second quarter 2025 financial results, highlighting a decrease in net sales and a leadership transition. The company, known for its innovative dental solutions, operates in the healthcare sector with a strong global presence.